Urogen Pharma Stock Price, News & Analysis (NASDAQ:URGN)

$49.83 -1.10 (-2.16 %)
(As of 02/23/2018 06:00 AM ET)
Previous Close$49.83
Today's Range$49.26 - $51.98
52-Week Range$13.01 - $56.56
Volume93,925 shs
Average Volume151,945 shs
Market Capitalization$687.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Urogen Pharma (NASDAQ:URGN)

Urogen Pharma logoUrogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601

Debt

Debt-to-Equity RatioN/A
Current Ratio15.79%
Quick Ratio15.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.53 million
Price / Sales39.09
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees33
Outstanding Shares13,750,000

Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

When will Urogen Pharma make its next earnings announcement?

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Friday, May, 4th 2018. View Earnings Estimates for Urogen Pharma.

Where is Urogen Pharma's stock going? Where will Urogen Pharma's stock price be in 2018?

6 analysts have issued 12 month price targets for Urogen Pharma's shares. Their predictions range from $25.00 to $51.00. On average, they anticipate Urogen Pharma's share price to reach $42.80 in the next twelve months. View Analyst Ratings for Urogen Pharma.

What are Wall Street analysts saying about Urogen Pharma stock?

Here are some recent quotes from research analysts about Urogen Pharma stock:

  • 1. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)
  • 2. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (10/18/2017)

Who are some of Urogen Pharma's key competitors?

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the folowing people:

  • Arie S. Belldegrun, Chairman of the Board (Age 67)
  • Ron Bentsur, Chief Executive Officer, Director (Age 51)
  • Gary S. Titus, Chief Financial Officer (Age 57)
  • Gil Hakim, President - Israeli Operation (Age 47)
  • Chaim Hurvitz, Director (Age 56)
  • Ran Nussbaum, Director (Age 44)
  • Kathryn E. Falberg, Independent Director (Age 56)
  • Stuart Holden M.D., Independent Director (Age 74)
  • Pini Orbach Ph.D., Independent Director (Age 52)

When did Urogen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who owns Urogen Pharma stock?

Urogen Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Consonance Capital Management LP (6.67%), Meitav Dash Investments Ltd. (3.00%), Perceptive Advisors LLC (1.45%), DSAM Partners London Ltd (0.99%), Renaissance Technologies LLC (0.95%) and Bainco International Investors (0.76%). View Institutional Ownership Trends for Urogen Pharma.

Who sold Urogen Pharma stock? Who is selling Urogen Pharma stock?

Urogen Pharma's stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. View Insider Buying and Selling for Urogen Pharma.

Who bought Urogen Pharma stock? Who is buying Urogen Pharma stock?

Urogen Pharma's stock was bought by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, Meitav Dash Investments Ltd., Renaissance Technologies LLC, DSAM Partners London Ltd, Deutsche Bank AG, Spark Investment Management LLC, Bainco International Investors and Lyon Street Capital LLC. View Insider Buying and Selling for Urogen Pharma.

How do I buy Urogen Pharma stock?

Shares of Urogen Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of Urogen Pharma stock can currently be purchased for approximately $49.83.

How big of a company is Urogen Pharma?

Urogen Pharma has a market capitalization of $687.57 million and generates $17.53 million in revenue each year. Urogen Pharma employs 33 workers across the globe.

How can I contact Urogen Pharma?

Urogen Pharma's mailing address is 9 HaTaasiya St, Raanana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]


MarketBeat Community Rating for Urogen Pharma (URGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  150
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Urogen Pharma (NASDAQ:URGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.803.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $42.80$42.80$41.00$28.00
Price Target Upside: 15.02% upside15.02% upside1.35% downside52.01% upside

Urogen Pharma (NASDAQ:URGN) Consensus Price Target History

Price Target History for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/2/2018Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$50.00HighView Rating Details
11/15/2017CowenReiterated RatingBuyN/AView Rating Details
11/15/2017CIBCReiterated RatingOutperform -> Outperform$32.00 -> $51.00N/AView Rating Details
11/15/2017Raymond James FinancialDowngradeOutperform -> Market PerformN/AView Rating Details
11/14/2017OppenheimerSet Price TargetOutperform$32.00 -> $51.00N/AView Rating Details
10/9/2017Jefferies GroupBoost Price TargetBuy$27.00 -> $37.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Urogen Pharma (NASDAQ:URGN) Earnings History and Estimates Chart

Earnings by Quarter for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ URGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2018        
11/14/2017Q3 2017$0.08($0.02)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.46)($0.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Urogen Pharma (NASDAQ:URGN) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.88 EPS
Next Year EPS Consensus Estimate: $-2.55 EPS

Dividends

Dividend History for Urogen Pharma (NASDAQ:URGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Urogen Pharma (NASDAQ URGN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 42.05%
Insider Trades by Quarter for Urogen Pharma (NASDAQ:URGN)
Insider Trades by Quarter for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ URGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2017Proquest Investments Iv, L.P.Major ShareholderSell209,298$40.60$8,497,498.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Urogen Pharma (NASDAQ URGN) News Headlines

Source:
DateHeadline
Urogen Pharma Ltd (URGN) Receives Consensus Rating of "Buy" from AnalystsUrogen Pharma Ltd (URGN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 23 at 3:30 AM
Research Analysts Set Expectations for Urogen Pharma Ltds Q4 2017 Earnings (URGN)Research Analysts Set Expectations for Urogen Pharma Ltd's Q4 2017 Earnings (URGN)
www.americanbankingnews.com - February 15 at 8:02 AM
Urogen Pharma (URGN) and Tyme Technologies (TYME) Head to Head ReviewUrogen Pharma (URGN) and Tyme Technologies (TYME) Head to Head Review
www.americanbankingnews.com - February 14 at 9:08 PM
Research Analysts Issue Forecasts for Urogen Pharma Ltds FY2022 Earnings (URGN)Research Analysts Issue Forecasts for Urogen Pharma Ltd's FY2022 Earnings (URGN)
www.americanbankingnews.com - February 14 at 4:12 PM
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating OfficerUroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
finance.yahoo.com - February 14 at 9:08 AM
Zacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.68 Earnings Per ShareZacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - February 6 at 12:36 PM
Urogen Pharma Ltd (URGN) Given Average Recommendation of "Buy" by AnalystsUrogen Pharma Ltd (URGN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 29 at 3:30 AM
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters OptionUroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
finance.yahoo.com - January 23 at 4:06 PM
UroGen Pharma Announces Pricing of Public Offering of Ordinary SharesUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
finance.yahoo.com - January 19 at 9:58 AM
UroGen Pharma Announces Proposed Public Offering of Ordinary SharesUroGen Pharma Announces Proposed Public Offering of Ordinary Shares
finance.yahoo.com - January 16 at 5:42 PM
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs OfficerUroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
finance.yahoo.com - January 8 at 10:49 AM
Urogen Pharma Ltd (URGN) Receives Average Rating of "Buy" from BrokeragesUrogen Pharma Ltd (URGN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 4 at 4:02 AM
Urogen Pharma (URGN) Research Coverage Started at Ladenburg Thalmann Financial ServicesUrogen Pharma (URGN) Research Coverage Started at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - January 2 at 11:04 AM
UroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare ConferenceUroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:01 AM
UroGen Pharma Ltd. breached its 50 day moving average in a Bearish Manner : URGN-US : January 1, 2018UroGen Pharma Ltd. breached its 50 day moving average in a Bearish Manner : URGN-US : January 1, 2018
finance.yahoo.com - January 1 at 9:01 AM
Urogen Pharma Ltd (URGN) Expected to Announce Earnings of -$0.68 Per ShareUrogen Pharma Ltd (URGN) Expected to Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - December 18 at 3:26 AM
UroGen Pharma Expands Clinical Development Leadership TeamUroGen Pharma Expands Clinical Development Leadership Team
finance.yahoo.com - December 12 at 9:27 AM
Urogen Pharma Ltd (URGN) Given Consensus Recommendation of "Buy" by BrokeragesUrogen Pharma Ltd (URGN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 10 at 3:50 AM
-$0.68 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter-$0.68 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter
www.americanbankingnews.com - November 30 at 1:26 AM
Proquest Investments Iv, L.P. Sells 209,298 Shares of Urogen Pharma Ltd (URGN) StockProquest Investments Iv, L.P. Sells 209,298 Shares of Urogen Pharma Ltd (URGN) Stock
www.americanbankingnews.com - November 29 at 7:24 PM
UroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual MeetingUroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting
finance.yahoo.com - November 27 at 3:46 PM
Wired News - Portola Pharmaceuticals Provides Update On Commercial Launch of Bevyxxa(R)Wired News - Portola Pharmaceuticals Provides Update On Commercial Launch of Bevyxxa(R)
finance.yahoo.com - November 27 at 8:30 AM
UROGEN PHARMA (URGN) Given a $51.00 Price Target by Oppenheimer Holdings, Inc. AnalystsUROGEN PHARMA (URGN) Given a $51.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 19 at 10:20 PM
UROGEN PHARMA (URGN) Downgraded to "Market Perform" at UBS AGUROGEN PHARMA (URGN) Downgraded to "Market Perform" at UBS AG
www.americanbankingnews.com - November 19 at 6:56 PM
Q4 2017 Earnings Estimate for Urogen Pharma (URGN) Issued By Jefferies GroupQ4 2017 Earnings Estimate for Urogen Pharma (URGN) Issued By Jefferies Group
www.americanbankingnews.com - November 17 at 10:12 PM
FY2017 EPS Estimates for Urogen Pharma Decreased by Oppenheimer Holdings (URGN)FY2017 EPS Estimates for Urogen Pharma Decreased by Oppenheimer Holdings (URGN)
www.americanbankingnews.com - November 17 at 7:12 PM
Raymond James Downgrades UroGen Pharma (URGN) to Market PerformRaymond James Downgrades UroGen Pharma (URGN) to Market Perform
www.streetinsider.com - November 16 at 9:40 AM
Urogen Pharmas (URGN) "Buy" Rating Reiterated at Cowen and CompanyUrogen Pharma's (URGN) "Buy" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - November 15 at 11:36 PM
Urogen Pharma (URGN) Given "Outperform" Rating at CIBCUrogen Pharma (URGN) Given "Outperform" Rating at CIBC
www.americanbankingnews.com - November 15 at 2:26 PM
Urogen Pharma (URGN) Downgraded to "Market Perform" at Raymond James Financial, Inc.Urogen Pharma (URGN) Downgraded to "Market Perform" at Raymond James Financial, Inc.
www.americanbankingnews.com - November 15 at 11:38 AM
Urogen Pharma (URGN) Receives Average Recommendation of "Buy" from AnalystsUrogen Pharma (URGN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 15 at 10:12 AM
UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate DevelopmentsUroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments
finance.yahoo.com - November 14 at 2:02 PM
 Analysts Anticipate Urogen Pharma (URGN) Will Announce Quarterly Sales of $7.67 Million Analysts Anticipate Urogen Pharma (URGN) Will Announce Quarterly Sales of $7.67 Million
www.americanbankingnews.com - November 13 at 5:14 PM
Zacks: Brokerages Anticipate Urogen Pharma (URGN) Will Announce Earnings of -$0.05 Per ShareZacks: Brokerages Anticipate Urogen Pharma (URGN) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - November 11 at 11:12 AM
Urogen Pharma (URGN) Set to Announce Earnings on TuesdayUrogen Pharma (URGN) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - November 10 at 9:56 AM
UroGen Pharma to Present at the Jefferies 2017 London Healthcare ConferenceUroGen Pharma to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 9 at 9:14 AM
 Urogen Pharma (URGN) Given Consensus Recommendation of "Strong Buy" by Analysts Urogen Pharma (URGN) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - November 7 at 10:59 AM
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive BladderUroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
finance.yahoo.com - November 6 at 8:43 AM
MyoKardia (MYOK) & UROGEN PHARMA (URGN) Financial AnalysisMyoKardia (MYOK) & UROGEN PHARMA (URGN) Financial Analysis
www.americanbankingnews.com - November 3 at 5:32 AM
ADMS Draws Attention, AAAP Buyout Rumor Becomes Real, GBT Exudes HOPEADMS Draws Attention, AAAP Buyout Rumor Becomes Real, GBT Exudes HOPE
www.nasdaq.com - October 31 at 11:30 AM
UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory AffairsUroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs
finance.yahoo.com - October 26 at 12:10 PM
Urogen Pharmas (URGN) Lock-Up Period Set To Expire  on October 31stUrogen Pharma's (URGN) Lock-Up Period Set To Expire on October 31st
www.americanbankingnews.com - October 24 at 1:06 AM
Analysts Expect Urogen Pharma (URGN) to Announce ($0.05) EPSAnalysts Expect Urogen Pharma (URGN) to Announce ($0.05) EPS
www.americanbankingnews.com - October 23 at 10:58 AM
Urogen Pharma (URGN) Price Target Raised to $37.00Urogen Pharma (URGN) Price Target Raised to $37.00
www.americanbankingnews.com - October 9 at 10:38 AM
Brokerages Anticipate Urogen Pharma (URGN) to Announce ($0.05) Earnings Per ShareBrokerages Anticipate Urogen Pharma (URGN) to Announce ($0.05) Earnings Per Share
www.americanbankingnews.com - October 7 at 6:50 PM
$7.67 Million in Sales Expected for UROGEN PHARMA (URGN) This Quarter$7.67 Million in Sales Expected for UROGEN PHARMA (URGN) This Quarter
www.americanbankingnews.com - October 5 at 6:46 AM
Zacks: Urogen Pharma (URGN) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Urogen Pharma (URGN) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - October 4 at 10:24 PM
U.S. IPO Week Ahead: Set-Top Boxes Top Off The Q3 2017 As Roku Headines 6-IPO WeekU.S. IPO Week Ahead: Set-Top Boxes Top Off The Q3 2017 As Roku Headines 6-IPO Week
seekingalpha.com - September 24 at 8:47 AM
Urogen Pharma (URGN) Expected to Post Earnings of -$0.05 Per ShareUrogen Pharma (URGN) Expected to Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - September 15 at 2:12 AM
Why This Cancer Biotech Leads Pack After Hitting Record HighWhy This Cancer Biotech Leads Pack After Hitting Record High
finance.yahoo.com - September 13 at 3:17 PM

SEC Filings

Urogen Pharma (NASDAQ:URGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Urogen Pharma (NASDAQ:URGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Urogen Pharma (NASDAQ URGN) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.